Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

 Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

Shots:

  • Parvus to receive an upfront & milestones exceeding $800M and royalties on sales of products targeting for IBD, ALD & Celiac diseases, and will conduct pre/clinical studies till P-I study. Additionally, will also obtain milestones & royalties on sales of products for other therapy areas
  • Roche to get WW license to develop and commercialize therapies utilizing Parvus’ Navacims platform for autoimmune disorders and will be responsible for their development post-P-I studies in addition to their regulatory submission
  • Parvus’ Navacims are precision medicine platform for autoimmune diseases by inducing immune tolerance without generalized immune suppression and targets disease pertinent TCR which restores the immune system balance

Click here to read full press release/ article | Ref: Parvus Therapaeutics | Image: Sky-Shine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post